Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Free Subscription


1 Am J Gastroenterol
1 Arch Virol
1 Eur J Gastroenterol Hepatol
2 Gut
1 Hepatology
1 Int J Cancer
2 J Hepatol
1 J Med Virol
6 J Viral Hepat
1 Pediatr Infect Dis J
2 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Gastroenterol

  1. YIM HJ, Kim W, Ahn SH, Yang JM, et al
    Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
    Am J Gastroenterol. 2020 May 1. doi: 10.14309/ajg.0000000000000605.
    PubMed         Abstract available

    Arch Virol

  2. SAID EM, Abdulaziz BA, El Kassas M, El Attar IH, et al
    High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life
    Arch Virol. 2020 Apr 30. pii: 10.1007/s00705-020-04639.
    PubMed         Abstract available

    Eur J Gastroenterol Hepatol

  3. HINRICHSEN H, Stoehr A, Cornberg M, Klinker H, et al
    Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759.
    PubMed         Abstract available


  4. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.

  5. LUTCKII A, Strunz B, Zhirkov A, Filipovich O, et al
    Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus.
    Gut. 2020 Apr 27. pii: gutjnl-2019-320269. doi: 10.1136/gutjnl-2019-320269.
    PubMed         Abstract available


  6. NAZZAL M, Sur S, Steele R, Khatun M, et al
    Establishment of a PDX tumor from Hepatitis C Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
    Hepatology. 2020 May 1. doi: 10.1002/hep.31298.
    PubMed         Abstract available

    Int J Cancer

  7. LI M, Shen Y, Chen Y, Gao H, et al
    Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma.
    Int J Cancer. 2020 Apr 29. doi: 10.1002/ijc.33027.
    PubMed         Abstract available

    J Hepatol

  8. KESSLER SM, Hoppstadter J, Hosseini K, Laggai S, et al
    Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation.
    J Hepatol. 2019 Jan 24. pii: S0168-8278(18)32569.

  9. BORST K, Graalmann T, Kalinke U
    Reply to: "Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation".
    J Hepatol. 2019 Jan 31. pii: S0168-8278(19)30013.

    J Med Virol

  10. KOC OM, Robaeys G, Topal H, Bielen R, et al
    Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: a long-term observational cohort study.
    J Med Virol. 2020 Apr 28. doi: 10.1002/jmv.25950.
    PubMed         Abstract available

    J Viral Hepat

  11. CHO JY, Sohn W, Paik YH, Gwak GY, et al
    Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients - functional cure unlikely.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13306.
    PubMed         Abstract available

  12. CARRASCO I, Sainz T, Antoinette Frick M, de Ory SJ, et al
    Response to Direct Acting Antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.
    J Viral Hepat. 2020 Apr 29. doi: 10.1111/jvh.13308.
    PubMed         Abstract available

  13. CHIU WN, Hung CH, Lu SN, Chen MY, et al
    Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection:a multicenter pooled analysis in Taiwan.
    J Viral Hepat. 2020 Apr 28. doi: 10.1111/jvh.13305.
    PubMed         Abstract available

  14. HONG CY, Sinn DH, Kang D, Paik SW, et al
    Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: Anationwide cohort study.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13304.
    PubMed         Abstract available

  15. YIP TC, Wong VW, Chan HL, Tse YK, et al
    Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13307.
    PubMed         Abstract available

  16. STROFFOLINI T, Ciancio A, Furlan C, Vinci M, et al
    Migratory flow and hepatitis Delta infection in Italy: a new challenge at the beginning of the third millennium.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13310.
    PubMed         Abstract available

    Pediatr Infect Dis J

  17. ZHOU H, Lu Y, Wu B, Che D, et al
    Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection.
    Pediatr Infect Dis J. 2020 Apr 24. doi: 10.1097/INF.0000000000002717.
    PubMed         Abstract available

    PLoS One

  18. WON YK, Kang KS, Gonzalez YS, Razavi H, et al
    A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    PLoS One. 2020;15:e0232186.
    PubMed         Abstract available

  19. HOSKING K, Stewart G, Mobsby M, Skov S, et al
    Data linkage and computerised algorithmic coding to enhance individual clinical care for Aboriginal people living with chronic hepatitis B in the Northern Territory of Australia - Is it feasible?
    PLoS One. 2020;15:e0232207.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  20. MICHAILIDIS E, Vercauteren K, Mancio-Silva L, Andrus L, et al
    Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes.
    Proc Natl Acad Sci U S A. 2020;117:1678-1688.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.